Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6940690 | 1.00 | HTT (0.59) | HTTFOLH1LMNASMN1; SMN2CTSK | |
| SCHEMBL6943807 | 0.89 | HTT (0.50) | HTTLMNASMN1; SMN2CTSKCTSS | |
| SCHEMBL6946489 | 0.89 | HTT (0.50) | HTTLMNASMN1; SMN2CTSKCTSS | |
| SCHEMBL2723527 | 0.87 | LMNA (0.52) | HTTLMNASMN1; SMN2CTSKCTSS | |
| SCHEMBL18086889 | 0.87 | CTSK (0.55) | HTTLMNASMN1; SMN2CTSKCTSS | |
| SCHEMBL6940875 | 0.87 | HSD17B10 (0.50) | HTTLMNASMN1; SMN2CTSKCTSS | |
| SCHEMBL6943800 | 0.87 | HSD17B10 (0.50) | HTTLMNASMN1; SMN2CTSKCTSS | |
| SCHEMBL7533308 | 0.86 | LMNA (0.51) | HTTLMNASMN1; SMN2CTSKCTSS | |
| SCHEMBL7535276 | 0.86 | LMNA (0.51) | HTTLMNASMN1; SMN2CTSKCTSS | |
| SCHEMBL2722875 | 0.86 | LMNA (0.51) | HTTLMNASMN1; SMN2CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177604-A1 | HETEROCYCLIC KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016022312-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-02-11 | — | — | WO | disclosed |
| US-6900237-B2 | Sulfonamide compounds as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | disclosed |
| WO-2003024923-A1 | SULFONAMIDE COMPOUNDS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | PRSS1, PRSS3, SPINT2 | HTT 3074/4885FOLH1 587/4885LMNA 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.